Today: 19 May 2026
D.R. Horton stock rises as KBW trims target — what Wall Street is watching next
12 January 2026
1 min read

D.R. Horton stock rises as KBW trims target — what Wall Street is watching next

NEW YORK, Jan 12, 2026, 15:07 (ET) — Regular session

  • D.R. Horton shares gained roughly 1% in afternoon trading, following the upward trend seen among other major homebuilders.
  • Keefe Bruyette & Woods lowered its price target for D.R. Horton to $168 from $175 but maintained a “Market Perform” rating.
  • Investors are zeroing in on D.R. Horton’s Jan. 20 earnings for new insights into demand, incentives, and profit margins heading into 2026.

D.R. Horton’s shares edged up roughly 1% to $158.82 Monday afternoon, even as Keefe Bruyette & Woods lowered its price target on the homebuilder. The firm cut the target to $168 from $175 but kept its market perform rating.

This move is significant as the sector has been reacting to minor tweaks in rate forecasts and policy talk. Investors are hunting for clues that affordability is improving or that builders might reduce incentives without hurting sales.

D.R. Horton faces a key test soon. Investors are gearing up ahead of its quarterly earnings next week, following a turbulent period for housing-related shares.

Keefe Bruyette & Woods lowered its price target to $168 from $175 but stuck with a “Market Perform” rating, according to MarketScreener. The report also noted that FactSet’s average target price hovers around the low $160s. MarketScreener

Shares of other major homebuilders climbed as well. Lennar rose roughly 0.9%, PulteGroup added about 0.7%, and Toll Brothers increased close to 1%.

D.R. Horton, the biggest U.S. homebuilder by volume, will report its first-quarter results for the period ending Dec. 31, 2025, on Jan. 20, before markets open. The company will hold a conference call at 8:30 a.m. ET that day, it said.

But the company has already cautioned that the road to a smoother spring selling season might be bumpy. In an Oct. 28 filing linked to its fiscal 2025 report, Executive Chairman David Auld noted that demand remains pressured by affordability issues. He added, “we expect our sales incentives to remain elevated in fiscal 2026,” with the exact level hinging on market conditions. The company also issued initial fiscal 2026 guidance, projecting revenue between $33.5 billion and $35.0 billion, along with roughly $2.5 billion in share buybacks. SEC

Housing stocks have been tossed around by news from Washington. On Jan. 9, homebuilders surged after President Donald Trump announced $200 billion in mortgage bond purchases to help lower housing costs. Analysts noted the move might tighten the spread between the 30-year mortgage rate and the 10-year Treasury yield.

D.R. Horton investors should watch Jan. 20 closely for clues on management’s tone, any changes to incentives or cancellations, and if order momentum is holding steady amid buyers’ sensitivity to monthly payments.

Stock Market Today

  • Big Tech Stocks Fuel Surge in Trump’s Trading Activity
    May 19, 2026, 6:05 AM EDT. President Trump's trading activity surged more than tenfold in the first quarter, driven by significant investments in Big Tech stocks including Nvidia and Dell. His money managers executed over 3,700 trades, marking a sharp increase compared to previous periods. The focus on major technology companies reflects a strategic shift from his earlier real estate ventures to high-value tech equities. This volume of trades indicates heightened market engagement and possibly a repositioning of his portfolio amid evolving market conditions.

Latest articles

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

19 May 2026
Virax Biolabs shares surged 53.1% Monday to $0.2350 and climbed another 17.1% in early Tuesday premarket trading, hitting $0.2751. The rally followed a paid RedChip TV appearance and a May 15 ownership filing showing Armistice Capital with a 4.99% stake. No new clinical or product updates were posted. Trading volume Monday reached about 765.2 million shares.
Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

19 May 2026
Amesite Inc. shares surged 218% to $2.50 in premarket trading after announcing its largest NurseMagic deployment with a 2,700-patient home-care client. The company disclosed $83,332 in quarterly revenue and a $678,061 net loss, with cash at $740,711 before a $2.2 million April financing. Amesite did not reveal the new contract’s value or customer name. Its latest filing cited “substantial doubt” about ongoing operations.
Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

Alphabet Approaches $5 Trillion With Google AI Cloud Move Targeting Nvidia

19 May 2026
Alphabet shares rose in pre-market trading Tuesday after Google and Blackstone announced a U.S. AI cloud venture, with Blackstone committing $5 billion to add 500 megawatts of data-center capacity by 2027. Alphabet’s Class A shares closed Monday at $396.94 and were quoted at $401.09 before the market opened. The move coincides with the first day of Google I/O and follows strong Q1 earnings.

Popular

Tesla Slides Again as Robotaxi Faces Latest Challenge

Tesla Slides Again as Robotaxi Faces Latest Challenge

18 May 2026
Tesla shares fell 3.8% to $406.11 Monday as tech stocks slid and bond yields rose. The company raised U.S. Model Y prices over the weekend, its first increase in two years. Elon Musk said Tesla expects to expand cars without human safety monitors across the U.S. later this year. Reuters tests of Tesla robotaxis in Texas found long waits and limited availability.
Harmony Gold stock jumps nearly 10% as gold cracks $4,600; CPI looms for HMY
Previous Story

Harmony Gold stock jumps nearly 10% as gold cracks $4,600; CPI looms for HMY

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR
Next Story

Lululemon stock rises after holiday-quarter outlook shifts to high end as LULU investors eye ICR

Go toTop